ReviewInfrastructure Requirements for Human Papillomavirus Vaccination and Cervical Cancer Screening in Sub-Saharan Africa
Highlights
► Primary prevention through HPV vaccination needs appropriate infrastructure. ► A major barrier to vaccine implementation is cost. ► Screening efforts in sub-Saharan Africa have largely focused on visual inspection. ► HPV DNA testing linked to treatment requires a low-cost technology/molecular test.
Introduction
Progress has been made on several fronts in the prevention of cervical cancer, both in primary prevention by vaccination and in screening, which will have substantial application in reducing cervical cancer incidence and mortality globally and in developing countries. The current high burden of cervical cancer in less developed countries is exemplified by the fact that more than 85% of cervical cancer cases (452,000 of 530,000 cases globally) and deaths (242,000 of 275,000 deaths globally) are observed in less developed countries [1]. The suboptimal performance of cytology screening programmes and challenges in implementing quality-assured Pap smear screening have stimulated the search for feasible and effective alternative screening strategies to reduce the burden of cervical neoplasia in such settings. Where applied successfully, as occurred in Scandinavian and other countries in the 1950s and beyond, there was a substantial reduction in the incidence of and mortality from cervical cancer following Pap smear programmes. However, requirements for traditional cytology screening programmes are prohibitively expensive and complex for initiation in the less developed countries of sub-Saharan Africa (SSA).
The lack of adequate infrastructure and human resources in health care services is a major impediment for implementing prevention strategies based on screening and human papillomavirus (HPV) vaccination in SSA. It is well recognised that creating appropriate infrastructure for cervical cancer prevention within the public health services is key to the success of prevention programmes. The lack of cervical cancer prevention programmes have resulted in a high burden of cervical cancer in SSA [2] and an increasing incidence of cervical cancer has been observed in some SSA countries such as Uganda [3]. SSA has the largest burden of human immunodeficiency virus (HIV) infection and the elevated risk of HPV infection among HIV-infected women further contributes to the high burden of cervical neoplasia in SSA. Thus, creating and improving infrastructure for cervical cancer prevention requires urgent attention from government authorities. The infrastructure requirements for implementing an integrated approach, based on HPV vaccination and screening in SSA, is briefly discussed in this paper.
Section snippets
Primary prevention of cervical cancer through vaccination
The aim of primary prevention is to prevent the initiation of cervical carcinogenesis and thus avoid occurrence of cervical cancer. Knowledge of the causes and co-factors that increase the risk of disease is vital for effective primary prevention strategies. It has been well-established that persistent infection with one of the oncogenic HPV types is the necessary cause for cervical cancer [4], [5]. HIV-infected women appear to be at a higher risk of persistent infection with HPV [6]. The
Cervical cancer prevention through secondary prevention
Secondary prevention of cervical cancer is based on the detection and effective treatment of cancer precursors through screening, leading to a reduction in the incidence of and mortality from invasive cancer. Effective cervical cancer prevention, especially in low-resource settings, should be focused on reaching women for screening at the time of the peak risk of treatable precancerous conditions due to persistent HPV infection and before the average age at which invasive cancers occur [16].
Infrastructure requirements for management of invasive cancer
Screening for cervical neoplasia, by whatever method, in a previously unscreened population will result in the diagnosis of invasive cervical cancer in both early and advanced stages and these will require proper staging and adequate treatment. It is unfortunate that adequate infrastructure is lacking in most SSA countries to manage invasive cancer. Staging will require assessment of the vagina, parametrium, urinary bladder and rectum by a combination of clinical and endoscopic procedures.
Conclusions
Reducing the high burden of cervical cancer substantially in less-developed countries has become a real possibility and achievable goal with the availability of HPV vaccination and feasible and effective alternatives to cytology screening. Political commitment, creative sources of financing and good planning in developing and augmentation of infrastructure and human resources for an integrated approach of vaccination, screening and treatment of women with cervical lesions is critically
Acknowledgements
The authors wish to thank Mrs. Evelyn Bayle, Ms. Sandrine Montigny, Ms. Karine Racinoux and Mrs. Krittika Guinot, IARC, for their help in the preparation of this manuscript.
Disclosed potential conflict of interest
RS, RA, GS-L: Have disclosed no potential conflicts of interest.
LD: Has received honoraria for appearing on various speaker fora for GlaxoSmithKline and Merck and Co. and sponsorship for research studies.
References (48)
- et al.
Clinical trials of cancer screening in the developing world and their impact on cancer healthcare
Ann Oncol
(2011) - et al.
Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study
Lancet Oncol
(2010) - et al.
A review of clinical trials of human papillomavirus prophylactic vaccines
Vaccine
(2012) - et al.
Implementation of human papillomavirus immunization in the developing world
Vaccine
(2012) - et al.
A critical assessment of screening methods for cervical neoplasia
Int J Gynaecol Obstet
(2005) - et al.
Accuracy of visual inspection with acetic acid for cervical cancer screening
Int J Gynaecol Obstet
(2011) - et al.
Visual screening for early detection of cervical neoplasia in Angola
Int J Gynaecol Obstet
(2010) - et al.
Cervical cancer screening with naked-eye visual inspection in Colombia
Int J Gynaecol Obstet
(2010) - et al.
Evaluation of cervical visual inspection screening in Dar es Salaam, Tanzania
Int J Gynaecol Obstet
(2010) - et al.
Effect of the “cough technique” on cryotherapy freezing temperature
Int J Gynaecol Obstet
(2010)
Performance of cryotherapy devices using nitrous oxide and carbon dioxide
Int J Gynaecol Obstet
Training for cervical cancer prevention programs in low-resource settings: focus on visual inspection with acetic acid and cryotherapy
Int J Gynaecol Obstet
A 5-day educational program for teaching cervical cancer screening using visual inspection with acetic acid in low-resource settings
Int J Gynaecol Obstet
Management of cryotherapy-ineligible women in a “screen-and-treat” cervical cancer prevention program targeting HIV-infected women in Zambia: lessons from the field
Gynecol Oncol
Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer
Vaccine
Nucleic acid tests for the detection of alpha human papillomaviruses
Vaccine
A new HPV-DNA test for cervical-cancer screening in developing regions: a cross-sectional study of clinical accuracy in rural China
Lancet Oncol
Benefits, cost requirements and cost-effectiveness of the HPV16,18 vaccine for cervical cancer prevention in developing countries: policy implications
Reprod Health Matters
Changing cancer incidence in Kampala, Uganda, 1991-2006
Int J Cancer
Human papillomavirus is a necessary cause of invasive cervical cancer worldwide
J Pathol
Human papillomavirus, cancer and vaccination
Curr Opin HIV AIDS
Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: Variation by geographical region, histological type and year of publication
Int J Cancer
Cited by (71)
Prevention of Cervical Cancer in Low-Resource African Settings
2022, Obstetrics and Gynecology Clinics of North AmericaTrends in cervical cancer screening research in sub-Saharan Africa: A bibliometric analysis of publications from 2001 to 2020
2022, Journal of Cancer PolicyCitation Excerpt :The World Health Organization (WHO) recommends cervical cancer screening for all women aged 30 years and older and beginning even earlier for some high-risk groups such as women living with HIV [6]. Cervical cancer screening facilitates early identification and effective treatment of cancer precursors, leading to a reduction in the incidence of and mortality from invasive cancer [7]. The uptake of cervical cancer screening in sub-Saharan Africa is significantly lower (5–35 % [8]) than in developed countries (41–81 % [9,10]).
Cancer in sub-Saharan Africa: a Lancet Oncology Commission
2022, The Lancet OncologyCitation Excerpt :Implementation of a cervical cancer screening programme using a pap smear has substantially decreased cervical cancer death in high-income countries. However, the establishment of such a programme requires infrastructure and trained personnel that are not readily available in many SSA countries.70 Visual inspection with acetic acid compared with cytology screening is advantageous because non-physician providers can perform the test with similar sensitivity at a lower cost than the pap smear.
Cost of community-based human papillomavirus self-sampling in Peru: A micro-costing study
2022, The Lancet Regional Health - AmericasCitation Excerpt :Although Peruvian women can receive a Pap test free of charge at public health centres,7 multiple barriers toward achieving high-quality cytology programs have been identified. These include an unequal regional concentration of lab facilities and clinics, inconsistency of procedures, distance, fear of the gynaecological examination, and shame.8-11 According to the Peruvian Demographic and Family Health Survey from 2015 to 2017, only 52·4% of women aged over 30 reported having had a Pap test in the last two years.12
Comparative assessment of test characteristics of cervical cancer screening methods for implementation in low-resource settings
2022, Preventive MedicineCitation Excerpt :In China, urine-based was compared with traditional HPV testing to improve access, which demonstrated lower specificity and sensitivity (Xu et al., 2020). Linking HPV testing with existing HIV prevention and treatment efforts may address implementation challenges and coverage (Sankaranarayanan et al., 2013). But test availability and subsequent follow-up protocols must be addressed before widespread primary HPV testing to avoid overtreatment and over-burdening of health systems (Bhatla and Singhal, 2020).